NCT01846143View on ClinicalTrials.gov

Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

June 30, 2015

Study Completion Date

November 30, 2015

Conditions
Melanoma
Interventions
BIOLOGICAL

pBCAR3-phosphopeptide

BIOLOGICAL

pIRS2-phosphopeptide

BIOLOGICAL

2-MpP (pBCAR3-phosphopeptide + pIRS2-phosphopeptide)

Trial Locations (1)

22908

University of Virginia, Charlottesville

All Listed Sponsors
lead

Craig L Slingluff, Jr

OTHER

NCT01846143 - Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies | Biotech Hunter | Biotech Hunter